Thursday, October 23, 2008

Lilly, Amylin enter into supply agreement for exenatide

Amylin Pharmaceuticals, Inc and Eli Lilly and Company have entered into a product supply agreement for exenatide once weekly, a development compound that, if approved, would become the first once weekly therapy to treat type-2 diabetes.

The details can be read here.

No comments: